PMID- 21142739
OWN - NLM
STAT- MEDLINE
DCOM- 20110329
LR  - 20141120
IS  - 1476-4180 (Electronic)
IS  - 1476-4172 (Linking)
VI  - 12
IP  - 6
DP  - 2010 Dec
TI  - An open-label trial examining the efficacy and safety of a pre- and postprocedure 
      topical five-product system (Clinique Medical Optimizing Regimen) specifically 
      formulated to complement laser/light-based facial cosmetic procedures.
PG  - 288-95
LID - 10.3109/14764172.2010.538407 [doi]
AB  - BACKGROUND: Specialized skin care regimens may help to minimize adverse events 
      (AEs) following non-ablative facial procedures. METHODS: A 14-week, open-label, 
      three-center study evaluated the efficacy and safety of a topical five-product 
      system (Clinique Medical Optimizing Regimen; Allergan, Inc., Irvine, CA, USA) for 
      minimizing localized AEs during two 6-week procedure cycles with fractionated 
      laser (FL) or intense pulsed light (IPL). The skin care regimen consisted of a 
      2-week preprocedure phase, a 1-week postprocedure phase, and a 3-week maintenance 
      phase. Investigators and patients rated the presence and severity of erythema, 
      itching, stinging/burning, edema, pain, pruritus, swelling, crusts/erosion, and 
      photodamage. RESULTS: Two days after the FL/IPL treatment (IPL: n = 27; FL: n = 
      21), most assessments, including erythema, were near baseline values; at 4 weeks 
      postprocedure, all investigator scores were comparable to baseline. Patients 
      missed work or avoided social situations a mean of only 0.8 days. Mean subject 
      ratings for itching, stinging/burning, pain, swelling, and redness for 2 weeks 
      postprocedure were 'none' to 'mild'. Treatment-related AEs (acne, facial rash) 
      occurred in four patients. All investigators stated they would recommend this 
      topical over-the-counter regimen again in conjunction with non-ablative FL/IPL 
      treatments. CONCLUSIONS: This topical five-product skin care system was safe and 
      effective in conjunction with non-ablative FL/IPL procedures.
FAU - Narurkar, Vic A
AU  - Narurkar VA
AD  - University of California, Davis, School of Medicine, Sacramento, CA, USA. 
      vicnarurkar@yahoo.com
FAU - Beer, Kenneth R
AU  - Beer KR
FAU - Cohen, Joel L
AU  - Cohen JL
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - J Cosmet Laser Ther
JT  - Journal of cosmetic and laser therapy : official publication of the European 
      Society for Laser Dermatology
JID - 101136419
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Dermatologic Agents)
RN  - 0 (Sunscreening Agents)
RN  - 3X7931PO74 (hydrocortisone acetate)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Administration, Topical
MH  - Adult
MH  - Aged
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Dermatologic Agents/*therapeutic use
MH  - Edema/etiology/prevention & control
MH  - Erythema/etiology/prevention & control
MH  - Female
MH  - Humans
MH  - Hydrocortisone/analogs & derivatives/therapeutic use
MH  - Laser Therapy/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Pain/etiology/prevention & control
MH  - Patient Satisfaction
MH  - Phototherapy/*adverse effects
MH  - Pruritus/etiology/prevention & control
MH  - Sunscreening Agents/therapeutic use
EDAT- 2010/12/15 06:00
MHDA- 2011/03/30 06:00
CRDT- 2010/12/15 06:00
PHST- 2010/12/15 06:00 [entrez]
PHST- 2010/12/15 06:00 [pubmed]
PHST- 2011/03/30 06:00 [medline]
AID - 10.3109/14764172.2010.538407 [doi]
PST - ppublish
SO  - J Cosmet Laser Ther. 2010 Dec;12(6):288-95. doi: 10.3109/14764172.2010.538407.